| Inner Knowing Clinical Therapy Llc | |
|
117 Brown Rd Durham ME 04222-5213 | |
| (207) 707-5129 | |
| Not Available |
| Full Name | Inner Knowing Clinical Therapy Llc |
|---|---|
| Speciality | Social Worker |
| Location | 117 Brown Rd, Durham, Maine |
| Authorized Official Name and Position | Carol Despres (CEO/OWNER) |
| Authorized Official Contact | 2077075129 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Inner Knowing Clinical Therapy Llc Pmb Box 354 190 Us Route 1 Falmouth ME 04105 Ph: (207) 707-5129 | Inner Knowing Clinical Therapy Llc 117 Brown Rd Durham ME 04222-5213 Ph: (207) 707-5129 |
| NPI Number | 1639781354 |
|---|---|
| Provider Enumeration Date | 08/24/2020 |
| Last Update Date | 08/24/2020 |
| Certification Date | 08/19/2020 |
| Medicare PECOS PAC ID | 2264845486 |
|---|---|
| Medicare Enrollment ID | O20210107002563 |
News Archive
HUYA Bioscience International, Founder, CEO & Executive Chair, Dr. Mireille Gillings today announced that the Ministry of Health, Labour and Welfare granted HBI-8000 orphan drug designation in Japan for peripheral T-cell lymphoma (PTCL).
New technologies that make the large-scale extraction of a natural antimalarial ‘wonder drug' both cheaper and greener are to be developed and trialled in a new European effort.
4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended resminostat for designation as orphan medicinal product for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
Health care professionals should become more familiar with medications that cause irregular heart rhythms called arrhythmias, according to "Drug- Induced Arrhythmias," a new scientific statement from the American Heart Association, published today in the Association's flagship journal Circulation.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639781354 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | (* (Not Available)) | Primary |
| Provider Name | Carol S Despres |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1366715856 PECOS PAC ID: 5597052399 Enrollment ID: I20160922000342 |
News Archive
HUYA Bioscience International, Founder, CEO & Executive Chair, Dr. Mireille Gillings today announced that the Ministry of Health, Labour and Welfare granted HBI-8000 orphan drug designation in Japan for peripheral T-cell lymphoma (PTCL).
New technologies that make the large-scale extraction of a natural antimalarial ‘wonder drug' both cheaper and greener are to be developed and trialled in a new European effort.
4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended resminostat for designation as orphan medicinal product for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
Health care professionals should become more familiar with medications that cause irregular heart rhythms called arrhythmias, according to "Drug- Induced Arrhythmias," a new scientific statement from the American Heart Association, published today in the Association's flagship journal Circulation.
› Verified 4 days ago
News Archive
HUYA Bioscience International, Founder, CEO & Executive Chair, Dr. Mireille Gillings today announced that the Ministry of Health, Labour and Welfare granted HBI-8000 orphan drug designation in Japan for peripheral T-cell lymphoma (PTCL).
New technologies that make the large-scale extraction of a natural antimalarial ‘wonder drug' both cheaper and greener are to be developed and trialled in a new European effort.
4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended resminostat for designation as orphan medicinal product for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
Health care professionals should become more familiar with medications that cause irregular heart rhythms called arrhythmias, according to "Drug- Induced Arrhythmias," a new scientific statement from the American Heart Association, published today in the Association's flagship journal Circulation.
› Verified 4 days ago